![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » LEO PHARMA AND WARNER CHILCOTT ANNOUNCE AGREEMENTS FOR EXPANSION OF COLLABORATION
LEO PHARMA AND WARNER CHILCOTT ANNOUNCE AGREEMENTS FOR EXPANSION OF COLLABORATION
September 16, 2005
LEO Pharma and U.S.-based Warner Chilcott have extended their co-operation to include the full LEO Pharma portfolio of present and future psoriasis treatments. Warner Chilcott is presently marketing Dovonex(R) under a co-promotion deal with Bristol-Myers Squibb Company (BMS) and is currently preparing for the launch of Dovobet(R) in the first half of 2006. "Dovobet(R) presents an exciting proposition for the treatment of psoriasis in the U.S., and we are preparing for its launch with great anticipation," said Roger Boissonneault, president and CEO of Warner Chilcott.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-15-2005/0004108642&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct